Hospital
Providence Health & Services Washington
Providence Health & Services Washington was paid $161.45M by Medicaid between Jan 2018 and Dec 2024, across 508 billing codes. Its largest line is 99285, emergency room visit (most serious) — 19% of everything it billed.
33Billing provider infoPROVIDENCE HEALTH & SERVICES WASHINGTON
ANCHORAGE, AK 99508
ANCHORAGE, AK 99508
33aNPI1053363119assigned 05/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$161.45M
24GClaims2,296,473
24DCodes billed508
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alaska
Rank by total paid#2 of 10
Median peer was paid$30.98M
This provider vs. median5.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 420,444 | $23.87M | |
| 2019 | 396,285 | $24.63M | |
| 2020 | 298,876 | $19.32M | |
| 2021 | 302,400 | $21.95M | |
| 2022 | 306,729 | $24.73M | |
| 2023 | 304,072 | $25.24M | |
| 2024incomplete | 267,667 | $21.73M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 46,022 | 39,502 | $30.97M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 56,881 | 49,082 | $22.32M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 68,480 | 60,469 | $16.42M |
| G0378 | Hospital observation service, per hour | 6.2% | 13,044 | 8,467 | $9.97M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 7,396 | 6,817 | $5.99M |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.1% | 2,217 | 2,087 | $5.03M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 44,491 | 37,871 | $3.14M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 8,043 | 7,360 | $3.00M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 34,449 | 28,150 | $2.61M |
| 71045 | Radiologic examination, chest; single view | 1.5% | 28,781 | 25,166 | $2.42M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 26,497 | 20,126 | $2.39M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 2,848 | 2,650 | $1.93M |
496 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 15,561 | $1.81M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,328 | $1.56M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 38,232 | $1.56M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,225 | $1.50M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 10,598 | $1.36M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 26,993 | $1.35M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 12,356 | $1.32M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 23,407 | $1.30M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,210 | $1.29M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 19,788 | $1.24M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,736 | $1.19M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 8,884 | $1.05M |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,783 | $1.01M |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,545 | $991K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 11,115 | $928K |
| 80053 | Comprehensive metabolic panel | <1% | 105,997 | $848K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,407 | $798K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,983 | $779K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,935 | $752K |
| J3490 | Unclassified drugs | <1% | 28,324 | $716K |
| 70496 | <1% | 1,484 | $710K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 115,033 | $669K |
| 96376 | <1% | 8,189 | $659K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 263 | $654K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,029 | $651K |
| 97597 | <1% | 7,556 | $650K | |
| 70498 | <1% | 1,510 | $634K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,315 | $631K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 16,752 | $590K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 70,969 | $572K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,389 | $542K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 16,210 | $537K |
| 88307 | <1% | 1,368 | $452K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,131 | $401K |
| 36430 | <1% | 1,990 | $400K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 991 | $395K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,258 | $385K |
| C1769 | Guide wire | <1% | 5,525 | $373K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,417 | $354K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 24,937 | $348K |
| 93971 | <1% | 1,781 | $339K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15,764 | $338K |
| 36902 | <1% | 1,199 | $324K | |
| 29581 | <1% | 4,276 | $321K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 427 | $318K |
| 36591 | <1% | 4,838 | $293K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,763 | $292K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 554 | $275K |
| 99153 | Mod sedat endo service >5yrs | <1% | 3,033 | $273K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,137 | $272K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,188 | $270K |
| 73610 | <1% | 2,163 | $259K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 12,807 | $258K |
| 88342 | <1% | 2,494 | $254K | |
| 97116 | <1% | 8,729 | $251K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,106 | $250K |
| 76801 | <1% | 1,092 | $237K | |
| 73562 | <1% | 1,982 | $219K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 23,396 | $218K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,736 | $217K |
| 73030 | <1% | 2,277 | $217K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 2,630 | $216K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,811 | $216K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 30,861 | $212K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,079 | $210K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 19 | $208K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,454 | $203K |
| 80061 | Lipid panel | <1% | 17,025 | $196K |
| 84484 | <1% | 27,789 | $192K | |
| 99152 | <1% | 3,756 | $192K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 5,666 | $183K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,696 | $179K |
| 70486 | <1% | 603 | $173K | |
| 74018 | <1% | 1,846 | $172K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,926 | $172K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,166 | $172K |
| 73130 | <1% | 1,727 | $171K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,391 | $165K |
| 83880 | <1% | 7,949 | $163K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 821 | $159K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 4,594 | $158K |
| 73630 | <1% | 1,575 | $156K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 503 | $155K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,190 | $153K |
| 96415 | <1% | 1,442 | $150K | |
| J2704 | Injection, propofol, 10 mg | <1% | 13,609 | $146K |
| H0007 | Alcohol and/or drug services; crisis intervention (outpatient) | <1% | 4,204 | $144K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 17,382 | $142K |
| 76830 | Ultrasound, transvaginal | <1% | 1,101 | $141K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 411 | $135K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 18,623 | $134K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 443 | $130K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 6,110 | $129K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 22,561 | $127K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 8,416 | $124K |
| 0240U | <1% | 1,177 | $123K | |
| 10061 | <1% | 720 | $123K | |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | <1% | 347 | $123K |
| D1120 | Dental cleaning, child | <1% | 403 | $122K |
| 72100 | <1% | 1,242 | $122K | |
| 83690 | <1% | 22,906 | $118K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,402 | $116K |
| C1732 | Catheter, electrophysiology, diagnostic/ablation, 3d or vector mapping | <1% | 54 | $115K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,212 | $112K |
| 81001 | <1% | 44,091 | $112K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 471 | $108K |
| 12001 | <1% | 1,047 | $107K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 86 | $107K |
| 81025 | <1% | 14,863 | $104K | |
| 87510 | <1% | 5,429 | $103K | |
| 87480 | <1% | 5,429 | $103K | |
| 87660 | <1% | 5,429 | $103K | |
| 86480 | <1% | 1,968 | $101K | |
| 97162 | <1% | 2,374 | $97K | |
| 86920 | <1% | 1,660 | $95K | |
| 90715 | <1% | 2,728 | $94K | |
| 87040 | <1% | 12,294 | $93K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,894 | $91K |
| 84702 | <1% | 6,647 | $90K | |
| 85027 | <1% | 19,082 | $90K | |
| 87150 | <1% | 2,959 | $90K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 16,990 | $89K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | <1% | 2,993 | $89K |
| 97129 | <1% | 1,096 | $87K | |
| 77336 | <1% | 830 | $87K | |
| 73590 | <1% | 783 | $86K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,194 | $81K |
| 96367 | <1% | 2,936 | $80K | |
| 86141 | <1% | 7,618 | $80K | |
| 83970 | <1% | 2,516 | $78K | |
| 73110 | <1% | 956 | $77K | |
| 93458 | <1% | 25 | $76K | |
| 84439 | <1% | 9,836 | $76K | |
| 73502 | <1% | 1,059 | $75K | |
| 87077 | <1% | 11,029 | $74K | |
| 97161 | <1% | 1,762 | $74K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,814 | $74K |
| 88341 | <1% | 507 | $73K | |
| 88304 | <1% | 1,606 | $72K | |
| 82728 | <1% | 6,360 | $72K | |
| 83605 | <1% | 9,558 | $69K | |
| 80074 | <1% | 1,824 | $68K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,099 | $68K |
| D1206 | Topical application of fluoride varnish | <1% | 236 | $67K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 270 | $66K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 811 | $65K |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 263 | $64K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 471 | $64K |
| 86780 | <1% | 5,629 | $64K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 6,620 | $63K |
| D1351 | Sealant - per tooth | <1% | 212 | $63K |
| 86803 | <1% | 4,984 | $63K | |
| 82077 | <1% | 5,077 | $61K | |
| 83735 | <1% | 13,047 | $61K | |
| 59025 | Fetal non-stress test | <1% | 649 | $59K |
| 94726 | <1% | 833 | $59K | |
| 84466 | <1% | 5,317 | $56K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 117,264 | $55K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 113 | $52K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,716 | $52K |
| 82607 | <1% | 4,325 | $51K | |
| 12011 | <1% | 523 | $51K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,231 | $51K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,017 | $51K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,326 | $51K |
| 73560 | <1% | 443 | $49K | |
| 92526 | <1% | 1,000 | $49K | |
| 82962 | <1% | 27,926 | $48K | |
| 82803 | <1% | 3,290 | $48K | |
| 88108 | <1% | 785 | $48K | |
| 87070 | <1% | 6,850 | $48K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 9,918 | $47K |
| 87186 | <1% | 5,538 | $46K | |
| 10060 | <1% | 410 | $46K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 289 | $45K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 289 | $45K |
| 97130 | <1% | 859 | $45K | |
| D0240 | <1% | 191 | $45K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,446 | $45K |
| 94729 | <1% | 951 | $44K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,064 | $43K |
| D0272 | Bitewings - two radiographic images | <1% | 179 | $43K |
| 86850 | <1% | 6,664 | $42K | |
| 93613 | <1% | 26 | $40K | |
| 94060 | <1% | 457 | $40K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,354 | $39K |
| 85610 | <1% | 15,069 | $39K | |
| 76818 | <1% | 200 | $39K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,421 | $38K |
| A9150 | Non-prescription drugs | <1% | 38,498 | $38K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 4,644 | $38K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,515 | $37K |
| 82570 | <1% | 8,292 | $37K | |
| 73140 | <1% | 493 | $36K | |
| 36907 | <1% | 90 | $36K | |
| 77334 | <1% | 65 | $36K | |
| 92523 | <1% | 432 | $35K | |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | <1% | 2,548 | $35K |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 1,258 | $35K |
| 96409 | <1% | 255 | $34K | |
| 73090 | <1% | 306 | $34K | |
| D2330 | <1% | 116 | $34K | |
| 80069 | <1% | 5,623 | $34K | |
| 85379 | <1% | 4,471 | $33K | |
| 93325 | <1% | 182 | $31K | |
| 97166 | <1% | 723 | $31K | |
| 76937 | <1% | 537 | $31K | |
| 84112 | <1% | 349 | $30K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 362 | $30K |
| 83540 | <1% | 5,648 | $30K | |
| 12002 | <1% | 326 | $30K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 88 | $29K |
| 93308 | <1% | 157 | $29K | |
| 97542 | <1% | 584 | $29K | |
| 90837 | Psychotherapy session, about an hour | <1% | 657 | $29K |
| 93798 | <1% | 752 | $28K | |
| 73080 | <1% | 274 | $28K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 262 | $28K |
| 84703 | <1% | 4,432 | $28K | |
| 97163 | <1% | 767 | $28K | |
| 82746 | <1% | 2,379 | $28K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,859 | $28K |
| 84145 | <1% | 1,765 | $27K | |
| 86140 | <1% | 6,093 | $27K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,566 | $27K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,376 | $27K |
| 85730 | <1% | 6,902 | $27K | |
| 82784 | <1% | 2,334 | $26K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 725 | $26K |
| 87081 | <1% | 3,748 | $26K | |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | <1% | 23 | $26K |
| 87340 | <1% | 3,113 | $25K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 90 | $24K |
| 97165 | <1% | 502 | $23K | |
| 82043 | <1% | 4,577 | $23K | |
| A6207 | Contact layer, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 4,042 | $23K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 3,886 | $23K |
| 73620 | <1% | 295 | $23K | |
| 87205 | <1% | 6,720 | $23K | |
| 93976 | <1% | 100 | $22K | |
| 96417 | <1% | 265 | $22K | |
| 82075 | <1% | 1,145 | $22K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 284 | $22K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,638 | $22K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 3,448 | $22K |
| 84403 | <1% | 1,046 | $22K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 562 | $21K |
| H2021 | Community-based wrap-around services, per 15 minutes | <1% | 1,378 | $21K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 77 | $21K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,114 | $21K |
| 94010 | <1% | 406 | $21K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,498 | $20K |
| 87640 | <1% | 792 | $20K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 448 | $20K |
| 87641 | <1% | 802 | $20K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 75 | $20K |
| D4355 | <1% | 69 | $20K | |
| 85652 | <1% | 8,764 | $20K | |
| 87631 | <1% | 199 | $20K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 624 | $19K |
| 76770 | <1% | 140 | $19K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,574 | $19K |
| 86900 | <1% | 8,619 | $19K | |
| 86901 | <1% | 8,606 | $19K | |
| 74174 | <1% | 27 | $19K | |
| 87075 | <1% | 2,594 | $19K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,202 | $18K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 39 | $18K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 467 | $18K |
| G0515 | Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes | <1% | 392 | $18K |
| 80076 | <1% | 2,542 | $18K | |
| 84100 | <1% | 4,988 | $17K | |
| 83516 | <1% | 1,333 | $17K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,992 | $17K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,125 | $17K |
| 80143 | <1% | 1,245 | $17K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 135 | $16K |
| 77295 | <1% | 12 | $16K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,861 | $16K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 12 | $16K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 292 | $16K |
| 82274 | <1% | 1,250 | $16K | |
| 80305 | <1% | 3,352 | $15K | |
| 80179 | <1% | 1,093 | $15K | |
| 86038 | <1% | 1,406 | $15K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,875 | $15K |
| 72040 | <1% | 163 | $15K | |
| 93312 | <1% | 30 | $14K | |
| 80197 | <1% | 1,376 | $14K | |
| 87522 | Neg quan hep c or qual rna | <1% | 355 | $14K |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,638 | $14K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,598 | $13K |
| 84481 | <1% | 903 | $13K | |
| 87653 | <1% | 297 | $13K | |
| 29125 | <1% | 127 | $13K | |
| 86762 | <1% | 873 | $12K | |
| 84156 | <1% | 3,907 | $12K | |
| 72170 | <1% | 114 | $11K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,340 | $11K |
| 82550 | <1% | 2,205 | $11K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,108 | $11K |
| 74230 | <1% | 73 | $10K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,856 | $10K |
| 87799 | <1% | 312 | $10K | |
| 84550 | <1% | 2,836 | $10K | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 108 | $10K |
| 96368 | <1% | 426 | $10K | |
| 86706 | <1% | 1,045 | $9K | |
| 94760 | <1% | 477 | $9K | |
| 77300 | <1% | 14 | $9K | |
| 82140 | <1% | 819 | $9K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 54 | $9K |
| 73120 | <1% | 99 | $8K | |
| 71101 | <1% | 69 | $8K | |
| 92611 | <1% | 59 | $8K | |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 1,662 | $8K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,944 | $8K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 149 | $8K |
| 86304 | <1% | 574 | $8K | |
| 0042T | <1% | 14 | $8K | |
| 70491 | <1% | 12 | $8K | |
| 84153 | <1% | 521 | $7K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,257 | $7K |
| 97602 | <1% | 151 | $7K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,022 | $7K |
| 81003 | <1% | 3,863 | $7K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 141 | $6K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 69 | $6K |
| 82310 | <1% | 1,688 | $6K | |
| 82977 | <1% | 895 | $6K | |
| 84146 | <1% | 338 | $6K | |
| 73600 | <1% | 47 | $6K | |
| 97127 | <1% | 59 | $6K | |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | <1% | 367 | $5K |
| 96450 | <1% | 14 | $5K | |
| 82150 | <1% | 945 | $5K | |
| 89051 | <1% | 1,228 | $5K | |
| 82657 | <1% | 187 | $5K | |
| 87493 | <1% | 187 | $5K | |
| 87497 | <1% | 180 | $5K | |
| 83615 | <1% | 1,143 | $5K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 668 | $5K |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 1,140 | $5K |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 26 | $5K |
| 82248 | <1% | 992 | $5K | |
| 80164 | <1% | 452 | $4K | |
| 82565 | <1% | 1,036 | $4K | |
| 87486 | <1% | 119 | $4K | |
| 87581 | <1% | 119 | $4K | |
| 87807 | <1% | 297 | $4K | |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | <1% | 15 | $4K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 164 | $4K |
| 78264 | <1% | 15 | $4K | |
| 71250 | <1% | 12 | $4K | |
| 36901 | <1% | 113 | $4K | |
| C1750 | Catheter, hemodialysis/peritoneal, long-term | <1% | 34 | $4K |
| 92610 | <1% | 55 | $4K | |
| 85014 | <1% | 2,393 | $4K | |
| D2332 | <1% | 14 | $4K | |
| 84460 | <1% | 801 | $4K | |
| 85018 | <1% | 2,028 | $4K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 44 | $4K |
| 86376 | <1% | 302 | $4K | |
| 87427 | <1% | 289 | $3K | |
| 49083 | <1% | 16 | $3K | |
| 82330 | <1% | 448 | $3K | |
| 87147 | <1% | 588 | $3K | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 180 | $3K |
| 87015 | <1% | 531 | $3K | |
| 83001 | <1% | 236 | $3K | |
| 82247 | <1% | 552 | $3K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 591 | $3K |
| C1788 | Port, indwelling (implantable) | <1% | 12 | $3K |
| A6457 | Tubular dressing with or without elastic, any width, per linear yard | <1% | 3,483 | $3K |
| C2623 | Catheter, transluminal angioplasty, drug-coated, non-laser | <1% | 46 | $3K |
| 82533 | <1% | 211 | $3K | |
| 82105 | <1% | 207 | $3K | |
| 84132 | <1% | 1,199 | $3K | |
| 97605 | <1% | 62 | $3K | |
| 83520 | <1% | 169 | $3K | |
| 83655 | <1% | 230 | $3K | |
| 86431 | <1% | 508 | $3K | |
| 76870 | <1% | 13 | $3K | |
| 73070 | <1% | 37 | $3K | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 207 | $2K |
| 86800 | <1% | 184 | $2K | |
| 74019 | <1% | 30 | $2K | |
| 85384 | <1% | 410 | $2K | |
| 83993 | <1% | 118 | $2K | |
| 88173 | <1% | 15 | $2K | |
| 87899 | <1% | 157 | $2K | |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 271 | $2K |
| 83525 | <1% | 193 | $2K | |
| 84305 | <1% | 100 | $2K | |
| 82670 | <1% | 108 | $2K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 36 | $2K |
| T1007 | Alcohol and/or substance abuse services, treatment plan development and/or modification | <1% | 13 | $2K |
| 86200 | <1% | 133 | $2K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 2,512 | $2K |
| 87046 | <1% | 169 | $2K | |
| 87045 | <1% | 168 | $2K | |
| 83002 | <1% | 101 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 161 | $2K |
| 86160 | <1% | 70 | $1K | |
| 82950 | <1% | 266 | $1K | |
| A6209 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 352 | $1K |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 163 | $1K |
| 87400 | <1% | 84 | $1K | |
| 73552 | <1% | 13 | $1K | |
| J9260 | Injection, methotrexate sodium, 50 mg | <1% | 23 | $1K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 33 | $1K |
| 86704 | <1% | 133 | $1K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 126 | $1K |
| 85045 | <1% | 216 | $980.23 | |
| 82785 | <1% | 57 | $932.02 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 15 | $924.90 |
| 84520 | <1% | 260 | $788.85 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 75 | $780.24 |
| 80178 | <1% | 135 | $767.14 | |
| 87536 | <1% | 12 | $748.86 | |
| 83013 | <1% | 13 | $714.00 | |
| 84450 | <1% | 166 | $713.43 | |
| H0046 | Mental health services, not otherwise specified | <1% | 621 | $689.12 |
| 84295 | <1% | 213 | $678.07 | |
| J2720 | Injection, protamine sulfate, per 10 mg | <1% | 130 | $625.73 |
| 86308 | <1% | 125 | $596.14 | |
| 84402 | <1% | 24 | $591.76 | |
| L1930 | Ankle foot orthosis, plastic or other material, prefabricated, includes fitting and adjustment | <1% | 16 | $544.52 |
| 85046 | <1% | 109 | $541.38 | |
| 86003 | <1% | 29 | $508.44 | |
| 86682 | <1% | 134 | $489.18 | |
| 82947 | <1% | 201 | $485.21 | |
| 82009 | <1% | 141 | $482.36 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 15 | $481.03 |
| A6199 | Alginate or other fiber gelling dressing, wound filler, sterile, per 6 inches | <1% | 49 | $456.24 |
| A6234 | Hydrocolloid dressing, wound cover, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 46 | $437.52 |
| 84134 | <1% | 33 | $429.38 | |
| 87116 | <1% | 43 | $395.08 | |
| 85347 | <1% | 452 | $379.51 | |
| J0735 | Injection, clonidine hydrochloride, 1 mg | <1% | 15 | $334.95 |
| 87209 | <1% | 28 | $322.74 | |
| L1836 | Knee orthosis, rigid, without joint(s), includes soft interface material, prefabricated, off-the-shelf | <1% | 16 | $322.65 |
| 86255 | <1% | 26 | $322.44 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 37 | $306.39 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 24 | $281.16 |
| 82010 | <1% | 46 | $269.61 | |
| 87102 | <1% | 26 | $263.40 | |
| 90686 | <1% | 64 | $261.92 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 752 | $243.68 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 267 | $215.00 |
| 87338 | <1% | 16 | $205.11 | |
| 87177 | <1% | 28 | $159.75 | |
| 87206 | <1% | 45 | $149.87 | |
| 87420 | <1% | 15 | $139.10 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 302 | $138.24 |
| 84165 | <1% | 17 | $112.20 | |
| 89060 | <1% | 15 | $100.95 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 15 | $95.48 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 29 | $91.55 |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 17 | $88.70 |
| 83014 | <1% | 13 | $83.34 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 23 | $81.84 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 13 | $78.36 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,149 | $75.98 |
| 0353U | <1% | 2,429 | $70.18 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 154 | $70.02 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 13 | $60.48 |
| 82945 | <1% | 12 | $47.16 | |
| 84157 | <1% | 12 | $44.02 | |
| 84155 | <1% | 18 | $42.06 | |
| 87207 | <1% | 14 | $41.33 | |
| A9270 | Non-covered item or service | <1% | 46,511 | $8.01 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 37 | $3.28 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 12,406 | $0.28 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 139 | $0.00 |
| 86364 | 0% | 718 | $0.00 | |
| 0352U | 0% | 1,763 | $0.00 | |
| 86258 | 0% | 82 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 214 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 88 | $0.00 |
| 0099U | 0% | 12 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 167 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 73 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 141 | $0.00 |
| 0031A | 0% | 84 | $0.00 | |
| 0011A | 0% | 33 | $0.00 | |
| 97802 | 0% | 38 | $0.00 | |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 38 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 520 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 372 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 81 | $0.00 |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | 0% | 49 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 470 | $0.00 |
| 86231 | 0% | 97 | $0.00 | |
| 80348 | 0% | 80 | $0.00 | |
| 90662 | 0% | 87 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY OF ENROLLMENTS)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.